The average twelve-month price target among analysts that have covered the stock in the last year is $15.00. Zacks Research lowered shares of Immatics from a “hold” rating to a “strong sell” rating in a research report on Friday, August 15th. Guggenheim assumed coverage on shares of Immatics in a research report on Thursday, September 18th. Check Out Our Latest Stock Report on IMTXImmatics Price PerformanceIMTX stock opened at $8.73 on Tuesday. Immatics Company Profile(Get Free Report)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.